In breast cancers with overexpression of low‐molecular‐weight cyclin E, ATR inhibition reduces cell viability by targeting the ATR–CHK1–RAD51 axis, underscoring the increased reliance of replication‐stress‐tolerant tumours on this pathway.96 Here, ATR is linked to breast carcinoma.